Evidence map›Paper›PMID 39378343›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial.

Hanne Lamberink, Sammy Huygens, Robina Aerts, Katrien Lagrou, Elena van Leeuwen-Segarceanu, Tom Lodewyck, Laurens Nieuwenhuizen, Maarten F Corsten, Ine Moors, Sophie Servais and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hanne LamberinkDepartment of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-2304-1353
Sammy HuygensDepartment of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-9418-8256
Robina AertsDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0001-6337-6636
Katrien LagrouDepartment of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.ORCID 0000-0001-8668-1350
Elena van Leeuwen-SegarceanuDepartment of Internal Medicine, St Antonius Hospital, Nieuwegein, The Netherlands.
Tom LodewyckDepartment of Hematology, AZ St-Jan Brugge-Oostende Hospital, Bruges, Belgium.ORCID 0000-0002-7570-0656
Laurens NieuwenhuizenDepartment of Hematology, Maxima Medical Center, Eindhoven/Veldhoven, The Netherlands.ORCID 0000-0002-0494-9374
Maarten F CorstenDepartment of Hematology, Meander Medical Center, Amersfoort, The Netherlands.ORCID 0000-0003-1326-4446
Ine MoorsDepartment of Hematology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0003-3079-8909
Sophie ServaisDepartment of Hematology, University Hospital of Liège, Liège, Belgium.ORCID 0000-0002-0238-6379
Julien De GreefDepartment of Internal Medicine and Infectious Diseases, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0003-0200-1237
Maya HitesClinic of Infectious Diseases, Hôpital Universitaire de Bruxelles, Brussels, Belgium.ORCID 0000-0001-6961-6039
Astrid DemandtDivision of Hematology, Department of Internal Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands.ORCID 0000-0003-4038-0231
Alexander SchauwvliegheDepartment of Hematology, AZ St-Jan Brugge-Oostende Hospital, Bruges, Belgium.ORCID 0000-0002-3224-3969
Johan MaertensDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Bart RijndersDepartment of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-3343-9610

Funding

Belgian-Netherlands Funding of International TrialsZonMw 80-85200-98-18558
6 · The paper itself

Abstract

The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

Indexed as

Antifungal AgentsAspergillosisAzolesEchinocandinsEquivalence Trials as TopicInvasive Pulmonary AspergillosisDrug Therapy, CombinationFemaleHumansMaleMiddle AgedTreatment OutcomeAntifungal AgentsAzolesEchinocandinsazolecombination therapyechinocandininvasive aspergillosis

Identifiers

PMID39378343
PMCPMC11848251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.